In:
Current Pharmaceutical Biotechnology, Bentham Science Publishers Ltd., Vol. 22, No. 11 ( 2021-08-03), p. 1511-1519
Abstract:
It has been found that there is a link between hypertension and elevated
risk of Alzheimer’s Disease (AD). Herein, a meta-analysis based on Randomized Clinical Trials (RCTs) was used to assess the effect of antihypertensive drugs on cognition and behavioral symptoms
of AD patients. Methods: The three databases, PubMed/Medline, Scopus, and Cochrane Library, were searched up
to March 2020. The quality of the studies included in the meta-analysis was evaluated by the Jadad score. Clinical Global Impression of Change (CGIC) included in two studies, Mini-Mental State
Examination (MMSE) included in three studies, and Neuropsychiatric Inventory (NPI) in three studies were the main outcomes in this systematic review. Results: Out of 1506 studies retrieved in the databases, 5 RCTs were included and analyzed in the
meta-analysis. The pooled mean differences of CGIC, MMSE, and NPI in patients with AD receiving antihypertensive drugs compared to placebo were -1.76 with (95% CI = -2.66 to -0.86;
P=0.0001), 0.74 (95% CI = 0.20 to 1.28; P= 0.007), and -9.49 (95% CI = -19.76 to 0.79; P = 0.07), respectively. Conclusion: The findings of the present meta-analysis show that antihypertensive drugs may improve
cognition and behavioral symptoms of patients with AD. However, more well-designed RCTs with similar drugs are needed to achieve more conclusive results.
Type of Medium:
Online Resource
ISSN:
1389-2010
DOI:
10.2174/1386207323666201211101720
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2021
SSG:
15,3
Bookmarklink